Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
GT Biopharma (GTBP)
NASDAQ:GTBP
GT Biopharma (GTBP) Stock Price & Analysis
175 Followers
GTBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.18 - $1.83
Previous Close$0.24
Volume47.17K
Average Volume (3M)126.61K
Market Cap
$9.61M
Enterprise Value-$8.24M
Total Cash (Recent Filing)$17.97M
Total Debt (Recent Filing)$120.00K
Price to Earnings (P/E)-0.8
Beta0.94
Next Earnings
Mar 27, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding41,418,999
10 Day Avg. Volume142,144
30 Day Avg. Volume126,615
Standard Deviation0.33
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.82
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio2402.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.65
Forecast
1Y Price Target
$5.00Price Target Upside1999.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
GT Biopharma News
Ownership Overview
0.00% Insiders
3.24% Mutual Funds
3.17% Other Institutional Investors
93.59% Public Companies and
Individual Investors
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.18 and its highest was $1.83 in the past 12 months.
What is GT Biopharma’s market cap?
Currently, no data Available
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Mar 27, 2024 which is in 111 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Nov 01, 2023. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.025.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -$0.09.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 41,419,000 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
---
GT Biopharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (1999.96% Upside)
$5.00 (1999.96% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.83%
12-Months-Change
Fundamentals
Return on Equity
-78.73%
Trailing 12-Months
Asset Growth
-23.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GT Biopharma
GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.
---
Top 5 ETFs holding GTBP
Vanguard Total Stock Market ETF
$201.45K
Up to five ETFs with an Outperform Smart Score that hold GTBP. The ETFs are listed according to market value of GTBP within the ETF
---